BiomX (NYSEAMERICAN:PHGE) Director Reuven Yeganeh Sells 450,000 Shares

BiomX Inc. (NYSEAMERICAN:PHGE) Director Reuven Yeganeh sold 450,000 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $5.00, for a total transaction of $2,250,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Reuven Yeganeh also recently made the following trade(s):

• On Tuesday, March 17th, Reuven Yeganeh sold 530,000 shares of BiomX stock. The shares were sold at an average price of $5.00, for a total transaction of $2,650,000.00.

BiomX Trading Down 3.6%

PHGE traded down $0.19 during trading hours on Wednesday, hitting $5.04. 52,934 shares of the company’s stock were exchanged, compared to its average volume of 1,183,020. The firm has a market cap of $8.01 million, a P/E ratio of -0.20 and a beta of 1.68. BiomX Inc. has a 12-month low of $1.50 and a 12-month high of $14.71. The firm has a 50 day moving average of $4.86 and a 200 day moving average of $6.36.

BiomX (NYSEAMERICAN:PHGE) last posted its quarterly earnings results on Thursday, February 19th. The company reported $6.99 EPS for the quarter. As a group, research analysts expect that BiomX Inc. will post -2.77 EPS for the current fiscal year.

Hedge Funds Weigh In On BiomX

A hedge fund recently bought a new stake in BiomX stock. Alyeska Investment Group L.P. purchased a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 1,590,738 shares of the company’s stock, valued at approximately $835,000. Alyeska Investment Group L.P. owned approximately 5.99% of BiomX at the end of the most recent reporting period. Institutional investors and hedge funds own 40.57% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright downgraded BiomX from a “buy” rating to a “hold” rating in a report on Monday, March 9th. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, BiomX presently has an average rating of “Hold” and a consensus target price of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.